These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25656881)

  • 81. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.
    Maurel J; Postigo A
    Curr Cancer Drug Targets; 2015; 15(8):703-15. PubMed ID: 26452385
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
    Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
    Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
    Sunakawa Y; Stintzing S; Cao S; Heinemann V; Cremolini C; Falcone A; Yang D; Zhang W; Ning Y; Stremitzer S; Matsusaka S; Yamauchi S; Parekh A; Okazaki S; Berger MD; Graver S; Mendez A; Scherer SJ; Loupakis F; Lenz HJ
    Ann Oncol; 2015 Dec; 26(12):2450-6. PubMed ID: 26416897
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.
    Nunes M; Vrignaud P; Vacher S; Richon S; Lièvre A; Cacheux W; Weiswald LB; Massonnet G; Chateau-Joubert S; Nicolas A; Dib C; Zhang W; Watters J; Bergstrom D; Roman-Roman S; Bièche I; Dangles-Marie V
    Cancer Res; 2015 Apr; 75(8):1560-6. PubMed ID: 25712343
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
    de la Rochefordiere A; Kamal M; Floquet A; Thomas L; Petrow P; Petit T; Pop M; Fabbro M; Kerr C; Joly F; Sevin E; Maillard S; Curé H; Weber B; Brunaud C; Minsat M; Gonzague L; Berton-Rigaud D; Aumont M; Gladieff L; Peignaux K; Bernard V; Leroy Q; Bieche I; Margogne A; Nadan A; Fourchotte V; Diallo A; Asselain B; Plancher C; Armanet S; Beuzeboc P; Scholl SM
    Clin Cancer Res; 2015 Jun; 21(11):2530-7. PubMed ID: 25724520
    [TBL] [Abstract][Full Text] [Related]  

  • 87. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.
    Giordano G; Parcesepe P; Bruno G; Piscazzi A; Lizzi V; Remo A; Pancione M; D'Andrea MR; De Santis E; Coppola L; Pietrafesa M; Fersini A; Ambrosi A; Landriscina M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299337
    [TBL] [Abstract][Full Text] [Related]  

  • 90. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.
    Cohen R; Svrcek M; Dreyer C; Cervera P; Duval A; Pocard M; Fléjou JF; de Gramont A; André T
    Curr Oncol Rep; 2016 Mar; 18(3):18. PubMed ID: 26861657
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Encorafenib (Braftovi) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):15-16. PubMed ID: 33512348
    [No Abstract]   [Full Text] [Related]  

  • 92. Cetuximab for metastatic colorectal cancer.
    Garattini S; Torri V; Floriani I
    N Engl J Med; 2009 Jul; 361(1):96; author reply 96-7. PubMed ID: 19579281
    [No Abstract]   [Full Text] [Related]  

  • 93. Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
    Cancer Discov; 2017 Mar; 7(3):242. PubMed ID: 28153858
    [TBL] [Abstract][Full Text] [Related]  

  • 94. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 95. Drug combo beneficial in colorectal cancer.
    Cancer Discov; 2015 Feb; 5(2):102. PubMed ID: 25656881
    [No Abstract]   [Full Text] [Related]  

  • 96. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
    van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
    Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.